Literature DB >> 8339566

Steroid treatment of myopic regression: acute refractive and topographic changes in excimer photorefractive keratectomy patients.

T D Fitzsimmons1, P Fagerholm, B Tengroth.   

Abstract

We documented acute changes in corneal topography and refraction after readministration of topical steroids in five patients with myopic regression after photorefractive keratectomy (PRK). One was a high myope (-10.00 sphere); the others were moderate myopes (preoperative spherical equivalents -4.25 to -6). All patients had been off steroids for 3 to 8 months before reinstitution. The changes in refractive spherical equivalents ranged from +0.75 to +3.00 diopters, and were observed from 6 days to 4 weeks later. Refractive hyperopic shifts were accompanied by pronounced corneal flattening as measured by computer-assisted corneal topographic analysis. Two to seven months later, three patients have become even less myopic, and two patients have again become slightly more myopic. Topical steroid use can modulate refractive changes after excimer laser treatments in some patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8339566     DOI: 10.1097/00003226-199307000-00013

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  3 in total

1.  Automated superficial lamellar keratectomy augmented by excimer laser masked PTK in the management of severe superficial corneal opacities.

Authors:  J L Alio; J Javaloy; J Merayo; A Galal
Journal:  Br J Ophthalmol       Date:  2004-10       Impact factor: 4.638

2.  Refractive and visual results and patient satisfaction after excimer laser photorefractive keratectomy for myopia.

Authors:  B L Halliday
Journal:  Br J Ophthalmol       Date:  1995-10       Impact factor: 4.638

3.  The variant N363S of glucocorticoid receptor in steroid-induced ocular hypertension in Hungarian patients treated with photorefractive keratectomy.

Authors:  Viktória Szabó; Gábor Borgulya; Tamás Filkorn; Judit Majnik; Ilona Bányász; Zoltán Zsolt Nagy
Journal:  Mol Vis       Date:  2007-04-27       Impact factor: 2.367

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.